Loading
A phase 1/2 trial of ivonescimab in lung cancer, run by GlaxoSmithKline, now recruiting.
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) is a phase 1/2, interventional study registered as NCT07602855 by GlaxoSmithKline, with a registry enrolment figure of 184 participants, started 2026-09-09 and due to reach its primary completion in 2029-06-22. Interventions recorded: Risvutatug rezetecan; Ivonescimab. Conditions listed: Neoplasms, Lung. Primary outcome: Phase 1 and Phase 2 Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) and Adverse events of special interest (AESIs); Phase 1 and Phase 2: Number of participants with AEs leading to dose modifications including study intervention discontinuation; Phase 2: Number of part. Lung eligibility wording from the registry: "ES-SCLC". Sites: Japan, United States. No results are recorded here; the registry entry is the source.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), Immune checkpoint inhibitors and the tag lung-deep-dive.